All In Biotech

Drug Trial Radar · NCT01873768

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty

Last checked: Nov 20, 2026Latest source record: Mar 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

194

Actual

Start

Jan 2014

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Miller Orthopedic SpecialistsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CHI Health Mercy Hospital; Creighton University Medical Center
First posted
Jun 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and EACA provide similar blood decreasing effects following TKA or whether one drug provides a superior effect over the other in reducing patients' blood loss.

Conditions

  • Osteoarthritis

Interventions

  • Tranexamic Acid (TXA)Drug

    1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.

  • ε-Aminocaproic Acid (EACA)Drug

    7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Transfusion rateTime frame: 1.5 to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Miller Orthopedic Specialists

    Council Bluffs, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.